Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2

Interventions

pembrolizumab 303Carboplatin 232Cisplatin 161Paclitaxel 154Gemcitabine 153Pemetrexed 123Bevacizumab 121Docetaxel 106durvalumab 83Oxaliplatin 82Nivolumab 82Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 79130-nm albumin-bound paclitaxel 74Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 57fludarabine 53Lenalidomide 51venetoclax 47Prednisone 45Letrozole 42Irinotecan 42enzalutamide 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × azeliragon × 90 days × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

NCT05986851 2026-03-31

Azeliragon in MGMT Unmethylated Glioblastoma

Cantex Pharmaceuticals

Phase 2 Active not recruiting
30 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡